Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference50 articles.
1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study;Fitzmaurice;JAMA Oncol.,2017
2. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am. J. Cancer Res. 08/15 07/23/received /27/accepted 2015;5(9):2892-2911.
3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med.,2009
4. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer;Soria;New England J. Med.,2018
5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012